Leronlimab is not going away but
Post# of 148282
(Total Views: 491)
Posted On: 08/21/2019 1:31:14 AM
Leronlimab is not going away but
the company can still go bankrupt. It happened with Achaogen and Synergy. Both failed because they didn't get commercialization right after approval and Achaogen had the added difficulty of only getting one of it's two crucial indications approved by the FDA (it is possible that the only approval leronlimab will ever get is for combo). Both drugs, Zemdri and Trulance, are still sold but shareholders were wiped out.
I'm not saying Cytodyn will go bankrupt, I have a lot of money in CYDY and I don't see that changing near term, but investing in microcap biotechs is very risky even after approval and I think it's very important to remember that leronlimab and Cytodyn are not one and the same. I think Nader has done a pretty good job delivering on promises this year but there are major pitfalls ahead that must be sidestepped before we get to a comfortable position with respect to revenue.
the company can still go bankrupt. It happened with Achaogen and Synergy. Both failed because they didn't get commercialization right after approval and Achaogen had the added difficulty of only getting one of it's two crucial indications approved by the FDA (it is possible that the only approval leronlimab will ever get is for combo). Both drugs, Zemdri and Trulance, are still sold but shareholders were wiped out.
I'm not saying Cytodyn will go bankrupt, I have a lot of money in CYDY and I don't see that changing near term, but investing in microcap biotechs is very risky even after approval and I think it's very important to remember that leronlimab and Cytodyn are not one and the same. I think Nader has done a pretty good job delivering on promises this year but there are major pitfalls ahead that must be sidestepped before we get to a comfortable position with respect to revenue.
(0)
(3)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼